Exon 6 variants carried on systemic lupus erythematosus (SLE) risk haplotypes modulate IRF5 function

Autoimmunity

Volumn 44, Issue 2, 2011, Pages 82-89

  Wen, Feng ^a,b   Ellingson, Sonja M ^b   Kyogoku, Chieko ^c   Peterson, Erik J ^b   Gaffney, Patrick M ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

apoptosis; exon 6; IRF5 variants; nuclear translocation; SLE

Indexed keywords

INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 6; LIPOPOLYSACCHARIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DNA DAMAGE; EMBRYO; EXON; GENETIC VARIABILITY; HAPLOTYPE; INDEL MUTATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; APOPTOSIS; CELL LINE; CELL NUCLEUS; CYTOKINES; EXONS; FIBROBLASTS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HAPLOTYPES; HUMANS; INTERFERON REGULATORY FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; PROTEIN ISOFORMS; RISK FACTORS;

EID: 79551560629     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2010.491842     Document Type: Article

References (25)

1. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, MizutaniT, Kano S, Honda K, Ohba Y, MakTW,TaniguchiT. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005;434:243-249.
2. Yanai H, Chen H, Inuzuka T, Kondo S, Mak TW, Takaoka A, Honda K, Taniguchi T. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc Natl Acad Sci USA 2007;104:3402-3407.
3. Cheng T, Brzostek S, AndoO, Scoy SV, Kumar KP, Reich NC. Differential activation of IFN regulatory factor (IRF)-3 and IRF-5 transcription factors during viral infection. J Immunol 2006;176:7462-7470.
4. Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LRL, Baechler EC, Plenge RM, Koeuth T, Ortmann WA, Hom G, Bauer JW, Gillett C, Burtt N, Cunninghame Graham DS, Onofrio R, Petri M, Gunnarsson I, Svenungsson E, Rönnblom L, Nordmark G, Gregersen PK, Moser K, Gaffney PM, Criswell LA, Vyse TJ, Syvänen AC, Bohjanen PR, Daly MJ, Behrens TW, Altshuler D. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci USA 2007;104:6758-6763.
5. Sigurdsson S, Gö ring HHH, Kristjansdottir G, Milani L, Nordmark G, Sandling JK, Eloranta ML, Feng D, Sangster-Guity N, Gunnarsson I, Svenungsson E, Sturfelt G, Jönsen A, Truedsson L, Barnes BJ, Alm G, Rönnblom L, Syvänen AC. Comprehsive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 2008;17:872-881.
6. Hu G, Mancl ME, Barnes BJ. Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. Cancer Res 2005; 65:7403-7412.
7. Hu G, Barnes BJ. IRF-5 is mediator of the death receptorinduced apoptotic signaling pathway. J Biol Chem 2009;284: 2767-2777.
8. Barnes BJ, Moore PA, Pitha PM. Virus-specific activation of novel interferon regulatory fator, IRF-5, results in the induction of distinct interferon a genes. J Biol Chem 2001; 276:23382-23390.
9. Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res 2003;63:6424-6431.
10. Yasuda K, Richez C, Maciaszek JW, Agrawal N, Akira S, Marshak-Rothstein A, Rifkin IR. Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J Immunol 2007;178:6876-6885.
11. Negishi H, Ohba Y, Yanai H, Takaoka A, Honma K, Yui K, Matsuyama T, Taniguchi T, Honda K. Negative regulation of Toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci USA 2005;102:15989-15994.
12. Mori T, Anazawa Y, Iiizumi M, Fukuda S, Nakamura Y, Arakawa H. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene 2002;21: 2914-2918.
13. Barnes BJ, Field AE, Pitha-Rowe PM. Virus-induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes. J Biol Chem 2003;278: 16630-16641.
14. Couzinet A, Tamura K, Chen H, Nishimura K, Wang ZC, Morishita Y, Takeda K, Yagita H, Yanai H, Taniguchi T, Tamura T. A cell-type-specific requiredment for IFN regulatory factor (IRF5) in Fas-induced apoptosis. Proc Natl Acad Sci USA 2008;105:2556-2561.
15. Levi BZ, Hashmueli S, Gleit-Kielmanowicz M, Azriel A, Meraro D. ICSBP/IRF-8 transactivation: A tale of proteinprotein interaction. J Interferon Cytokine Res 2002;22: 153-160.
16. Dideberg V, Kristjansdottir G, Milani L, Libioulle C, Sigurdsson S, Louis E, Wiman AC, Vermeire S, Rutgeerts P, Belaiche J, Franchimont D, Van Gossum A, Bours V, Syvänen AC. An insertion-deletion polymorphism in the interferon regulatory factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Human Mol Genetics 2007;16: 3008-3016.
17. Samuelson LC, Metzger JM. Isolation and freezing of primary mouse embryonic fibroblasts (MEF) for feeder plates. Cold Spring Harb Protoc 2006;Issue 2:4482.
18. Van Der Haegen BA, Shay JW. Immortalization of human mammary epithelial cells by SV40 large T-antigen involves a two step mechanism. In Vitro Cell Dev Biol 1993;29A: 180-182.
19. Graham RR, Kozyrev SV, Baechler EC, Linga Reddy PMV, Plenge RM, Bauer JW, Ortmann WA, Koeuth T, González-Escribano MF, the Argentine and Spanish Collaborative Groups, Pons-Estel B, Petri M, Daly M, Gregersen PK, Martín J, Altshuler D, Behrens TW, Alarcón-RiquelmeME. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nature Genetics 2006;38:550-555.
20. Mancl ME, Hu G, Sangster-Guity N, Olshalsky SL, Hoops K, Fitzgerald-Bocarsly P, Pitha PM, Pinder K, Barnes BJ. Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. J Biol Chem 2005;280: 21078-21090.
21. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V. J Immunol Meth 1995;184(1): 39-51.
22. Barnes BJ, Kellum MJ, Field AE, Pitha PM. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol 2002;22(16): 5721-5740.
23. Lin R, Yang L, Arguello M, Penafuerte C, Hiscott J. A CRM1-dependent nuclear export pathway is involved in the regulation of IRF-5 subcellular localization. J Biol Chem 2005;280(4): 3088-3095.
24. Yang L, Zhao T, Shi X, Nakhaei P, Wang Y, Sun Q, Hiscott J, Lin R. Functional analysis of a dominant negative mutation of interferon regulatory factor 5. PLoS ONE 2009;4(5):e5500, doi:10.1371/journal.pone.0005500.
25. Koyzyrev SV, Lewén S, Linga Reddy PMV, Pons-Estel B and the Argentine Collaborative Group, Witte Tand the German Collaborative Group, Junker P, Laustrup P, Gutiérrez C, Suárez A, González-Escribano MF, Martín J and the Spanish Collaborative Group, Alarcón- Riquelme. Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus. Arthritis Rheumat 2007;56(4): 1234-1241.